文献速递肝病

索磷布韦联合维帕他韦联合或不联合利巴韦林治疗基因3型丙型肝炎病毒感染合并肝硬化患者的疗效

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
PubMed 文献 · Gastroenterology · 2018-06-27

这项2期试验在西班牙29个中心纳入204例基因3型丙型肝炎病毒感染合并代偿期肝硬化患者,随机接受索磷布韦联合维帕他韦治疗12周(n=101)或再加用利巴韦林治疗12周(n=103)。总体持续病毒学应答12周(SVR12)率分别为91%和96%;不含利巴韦林组中基线NS5A耐药相关替换(RAS)阳性者SVR12率低于阴性者。

要点

  • 索磷布韦联合维帕他韦治疗12周SVR12为91%(92/101),加用利巴韦林组为96%(99/103)。
  • 不含利巴韦林组基线NS5A RAS阳性者SVR12为84%,阴性者为96%。
  • 含利巴韦林组基线RAS阳性者SVR12为96%,阴性者为99%。

核心结论

  • 与既往研究一致,基因3型丙型肝炎病毒感染合并代偿期肝硬化患者接受索磷布韦联合维帕他韦联合或不联合利巴韦林治疗可获得高SVR12率(91%和96%)。
  • 在不含利巴韦林方案中,基线NS5A RAS阳性患者达到SVR12的比例低于阴性患者。

研究设计与样本

  • 2期试验,2016年8月19日至2017年4月18日在西班牙29个中心纳入204例基因3型丙型肝炎病毒感染合并代偿期肝硬化患者(平均年龄51±7.4岁)。
  • 患者被分配至索磷布韦联合维帕他韦治疗12周组(n=101)或索磷布韦联合维帕他韦加利巴韦林治疗12周组(n=103)。
  • 主要疗效终点为SVR12。

主要发现

  • 索磷布韦联合维帕他韦组总体SVR12为91%(92/101;95%CI 84-96),索磷布韦联合维帕他韦加利巴韦林组为96%(99/103;95%CI 90-99)。
  • 索磷布韦联合维帕他韦组中,基线NS5A RAS阳性患者SVR12为84%,阴性患者为96%。
  • 索磷布韦联合维帕他韦加利巴韦林组中,基线RAS阳性患者SVR12为96%,阴性患者为99%。
  • 索磷布韦联合维帕他韦组最常见不良事件(发生率≥10%)为乏力(12%)。
  • 索磷布韦联合维帕他韦加利巴韦林组最常见不良事件(发生率≥10%)为乏力(27%)、头痛(24%)和失眠(12%)。

关键数值与推荐

  • 索磷布韦联合维帕他韦组SVR12为91%(92/101;95%CI 84-96)。
  • 索磷布韦联合维帕他韦加利巴韦林组SVR12为96%(99/103;95%CI 90-99)。
  • 索磷布韦联合维帕他韦组基线NS5A RAS阳性者SVR12为84%,阴性者为96%。
  • 索磷布韦联合维帕他韦加利巴韦林组基线RAS阳性者SVR12为96%,阴性者为99%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and velpatasvir than in patients without cirrhosis. It is unclear whether adding ribavirin to this treatment regimen increases SVRs in patients with genotype 3 HCV infection and cirrhosis. METHODS: We performed a phase 2 trial of 204 patients with genotype 3 HCV infection and compensated cirrhosis (mean age 51 ± 7.4 years) at 29 sites in Spain from August 19, 2016 through April 18, 2017. Patients were assigned to groups given sofosbuvir and velpatasvir for 12 weeks (n = 101) or sofosbuvir and velpatasvir plus ribavirin for 12 weeks (n = 103). The primary efficacy end point was SVR12. RESULTS: The overall rates of SVR12 were 91% (92 of 101; 95% CI 84-96) for the sofosbuvir-velpatasvir group and 96% (99 of 103; 95% CI 90-99) for the sofosbuvir-velpatasvir plus ribavirin group. In the sofosbuvir-velpatasvir group, a smaller proportion of patients with baseline resistance-associated substitutions (RASs) in nonstructural protein 5A (NS5A) achieved an SVR12 (84%) than did patients without (96%). In the sofosbuvir-velpatasvir plus ribavirin group, baseline RASs had less effect on the proportion of patients with an SVR12 (96% for patients with baseline RASs; 99% for patients without). The most common adverse events (which occurred in ≥10% of patients) were asthenia (12%) in the sofosbuvir-velpatasvir group and asthenia (27%), headache (24%), and insomnia (12%) in the sofosbuvir-velpatasvir plus ribavirin group. CONCLUSIONS: Consistent with findings from previous studies, a high rate of patients (91% and 96%) with genotype 3 HCV infection and compensated cirrhosis achieved an SVR12 with sofosbuvir and velpatasvir, with or without ribavirin. Of patients treated with sofosbuvir and velpatasvir without ribavirin, fewer patients with baseline NS5A RASs achieved an SVR12 compared with patients without baseline NS5A. ClinicalTrials.govNCT02781558.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Esteban R, Pineda JA, Calleja JL, et al. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. Gastroenterology. 2018. PMID: 29958855. doi:10.1053/j.gastro.2018.06.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。